In a recent proteomic analysis of circulating EVs in BC patients, profiling of cancer-associated proteins from plasma EVs without the interference of soluble proteins resulted in a EV protein signature (a weighted sum of eight EV protein markers; carcinoma antigen 15-3 (Ca15-3)), carcinoembryonic antigen (CEA), cancer antigen 125 (Ca125), HER2, EGFR, prostate-specific membrane antigen (PSMA), EpCAM and VEGF with a high accuracy (91.1%) for discrimination between metastatic BC, non-metastatic BC and healthy controls. Here, FOLH1 is linked to cancer.